Background: Secondary cancer is the most life-threatening late effect of childhood cancer. We investigated the clinical features of secondary bone/soft tissue sarcoma among childhood cancer survivors (CCSs). Methods: We conducted a retrospective case-series study of 10 069 CCSs newly diagnosed with cancer between 1980 and 2009 across 15 Japanese hospitals. Twenty-one cases of pathologically diagnosed secondary bone/soft tissue sarcoma were selected, and the respective clinical courses were determined using additional questionnaires. Results: The primary cancers included retinoblastoma (n = 7), acute lymphoblastic leukemia (n = 5), lymphoma (n = 5), osteosarcoma (n = 1), rhabdomyosarcoma (n = 1), brain tumor (n = 1) and Langerhans cell histiocytosis (n = 1). The median age at the primary cancer diagnosis was 2.9 years, and the male-to-female ratio was 16:5. The histological classifications of the secondary sarcoma included osteosarcoma (n = 10), malignant peripheral nerve sheath tumor (n = 4), rhabdomyosarcoma (n = 3), Ewing's sarcoma (n = 3) and primitive neuroectodermal tumor (n = 1). The median latency period to the secondary sarcoma was 10.2 years. Significant risk factors for secondary sarcoma in the multivariate Cox regression model included a history of retinoblastoma as the primary cancer (hazard ratio [HR], 20.9; 95% confidence interval [CI], 5.70-76.5) and autologous stem cell transplantation (SCT) (HR, 2.56; 95% CI, 1.08-6.03). Seventeen CCSs with secondary sarcoma underwent radiation, and nine,
Introduction
Despite significant improvements in childhood cancer, childhood cancer survivors (CCSs) still develop various subsequent late effects including the development of secondary cancer, which is the leading cause of mortality (1, 2) . The Childhood Cancer Survivor Study (CCSS) (3, 4) and the British CCSS (BCCSS) (5) have reported that CCSs are at an increased risk of subsequent neoplasms. However, the prevalence of bone/soft tissue sarcomas is relatively low, accounting for only 10-15% of all cases of secondary cancers among CCSs (6, 7) . Thus, few reports have detailed the clinical characteristics of secondary sarcoma including its treatment and prognoses (8, 9) . Pre-existing genetic conditions, such as Li-Fraumeni syndrome, may predispose children and young adults to sarcoma (10) . Moreover, whether secondary sarcomas can be treated via the same strategies used for de novo childhood sarcomas remains unclear (9) .
A previous nationwide survey in Japan showed that the 10-and 20-year cumulative incidence rate of secondary cancers in Japan is 1.1% (95% confidence interval [CI] , 0.9-1.4) and 2.6% (95% CI, 2.1-3.3) (11) . Of the 128 secondary cancers, 21 (16%) were bone/ soft tissue sarcomas, including four malignant peripheral nerve sheath tumors (MPNST). Herein, we aimed to investigate the clinical features of secondary bone/soft tissue sarcoma among CCSs in Japan (11) . Toward this goal, we conducted a retrospective caseseries study of CCSs diagnosed between 1980 and 2009 across 15 Japanese hospitals.
Materials and methods

Study population
The retrospective cohort population initially comprised 10 517 children who were newly diagnosed with cancer across 15 hospitals in Japan between 1980 and 2009. After screening using the following inclusion criteria, 10 069 patients were included: age <16 years at the time of the primary cancer diagnosis, survival ≥2 months after the diagnosis, and available outcome information (11) . Of these, we selected 21 cases of pathologically diagnosed secondary bone/soft tissue sarcoma and evaluated the clinical characteristics using the additional information obtained through a second survey.
Data collection and follow-up
The diagnostic and treatment data for the primary cancers were obtained from the 15 treating hospitals, which have been listed in the Acknowledgments section. We administered a second survey in these treating hospitals to collect the following data on the secondary cancer: date of diagnosis, cytological or histological findings including cytogenetic findings, cancer site, cumulative treatment exposure before the secondary cancer development and outcomes.
The period at risk for secondary cancer was computed from the date of the primary cancer diagnosis to the date of the secondary cancer diagnosis, date at the time of death or date of last contact, whichever came first. The age at diagnosis and last follow-up and the latency period for secondary cancer were all calculated as real numbers with decimal points. The follow-up period ended on 31 March 2010. . The doses of daunorubicin, doxorubicin, pirarubicin and mitoxantrone were added to determine the cumulative anthracycline dose (doxorubicin equivalents: daunorubicin × 0.83, doxorubicin × 1, pirarubicin × 0.6 and mitoxantrone × 4) and were divided into three categories: 0, <250 mg/m 2 and ≥250 mg/m 
Cancer and treatment categories
Statistical analysis
The descriptive statistics reported included the following: proportions, medians and ranges (min-max). A nonparametric Wilcoxon rank sum test or Kruskal-Wallis test was used for between-group comparisons of the continuous or ordinal variables, respectively. Fisher's exact test was used for comparing categorical variables. The cumulative incidence of secondary cancers was calculated using the competing risk method (considering any death as a competing event) (12) . Survival analysis was conducted using the Kaplan-Meier method (log-rank method for comparison), and a Cox regression model analysis was performed for hazard ratio (HR) estimates. Data were analyzed using SPSS version 22.0 (IBM Japan Ltd, Tokyo, Japan) and EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (13) . More precisely, it is a modified version of R commander designed to conduct statistical analysis frequently used in biostatistics (13) .
Ethics
The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the principal investigator's institution (Y. Ishida, St. Luke's International Hospital, Approval No. 09-124). The study was also approved by the local ethics committees of all the participating hospitals prior to initiation.
Results
Patient characteristics
The characteristics of the patients with secondary sarcoma are shown in Table 1 . The primary cancers included retinoblastoma (n = 7), ALL (n = 5), NHL (n = 5), OS (n = 1), RMS (n = 1), brain tumor (pineal germ cell tumor) (n = 1), and LCH (n = 1). All cases of sarcoma secondary to retinoblastoma developed in the survivors with bilateral and hereditary retinoblastoma. The median age at the diagnosis of primary cancer was 2.9 years (range, 0.1-14.4 years), and the male-to-female ratio was 16:5. The histological classifications of secondary sarcoma included OS (n = 10), MPNST (n = 4), RMS (n = 3), ES (n = 3), and PNET (n = 1). The median latency period from primary cancer diagnosis to the secondary cancer was 10.2 years (range, 1.5-21.2 years). Seventeen of the 21 CCSs with secondary sarcoma received radiation therapy, with doses ranging between 12 Gy and 76 Gy applied to various sites (Fig. 1C ). In-field and out-of-field secondary sarcomas developed in 13 (76%) and 4 (24%) of 17 CCSs, respectively. Nine CCSs received autologous SCT (Auto-SCT) ( Fig. 1F ). At the time of the most recent follow-up, 12 CCSs with secondary sarcoma had disease-free survival.
Secondary sarcoma incidence
Twenty-one CCSs developed secondary bone/soft tissue sarcoma. The overall cumulative incidence of secondary sarcoma was 0.2% (95% CI, 0.1-0.4) at 10 years and 0.7% (95% CI, 0.3-1.2) at 20 years from the time of primary cancer diagnosis. The 20-year cumulative incidence of secondary sarcoma in the retinoblastoma, hematological cancer and other solid cancer groups were 6.7% (95% CI, 1.6-17.0), 0.3% (95% CI, 0.1-0.6) and 0.6% (95% CI, 0.2-1.3), respectively (Fig. 1B) . Radiotherapy, surgery and Auto-SCT were the factors that significantly influenced the incidence of secondary sarcoma in the univariate competing risk analysis.
Clinical characteristics of the secondary sarcomas according to the primary cancer group
The clinical characteristics of the CCSs with secondary sarcoma according to the three primary cancer categories are summarized in Table 2 . The age at the diagnosis of primary cancer was significantly lower in the retinoblastoma group. More women were diagnosed with secondary sarcoma in the retinoblastoma group, while more men were diagnosed with secondary sarcoma in the hematological cancer and other solid cancer groups. The secondary sarcoma types were strongly correlated with the primary cancer types (P = 0.003); OS was highly prevalent in the retinoblastoma group (71%), while nerve-related sarcomas (MPNST and PNET) developed only in the hematological cancer group (50%). The proportions of secondary sarcoma after radiation therapy were significantly lower in the other solid cancer group than those in the retinoblastoma and hematological cancer groups. The cumulative dose distributions of anthracyclines and CDDP were different between the three groups; higher doses of anthracyclines were common in the hematological cancer group, while higher doses of CDDP were common in the other solid cancer group. In the multivariate Cox regression model, the significant risk factors for secondary sarcoma were a history of retinoblastoma as the primary cancer (HR, 20.9; 95% CI, 5.70-76.5; P < 0.001) and Auto-SCT (HR, 2.56; 95% CI, 1.08-6.03; P = 0.032) in the multivariate Cox regression model (Table 3) . The median latency period to secondary sarcoma varied marginally according to the primary cancer group and secondary cancer type (Supplemental Fig. A and B) . The age at secondary sarcoma development is shown in Supplemental Fig. C , and more than 50% of the CCSs in the retinoblastoma group developed the secondary sarcoma at less than 6 years of age.
The Kaplan-Meier survival curves for the CCSs with secondary sarcomas are shown in Fig. 2 . Log-rank test showed that the proportion of those who achieved disease-free survival tended to be lower in the hematological cancer group (30%, as shown in Table 2 ), and the CCSs with secondary sarcoma in this group tended to have worse prognoses than those with secondary sarcoma in the retinoblastoma and other solid cancer groups (P = 0.098) (Fig. 2A ). There were no differences in survival according to the secondary sarcoma type, use of radiation therapy (Fig. 2C) , and CDDP dose (Fig. 2D) . Anthracycline use and relapse of primary cancers were related to poor survival among the CCSs with secondary sarcoma (Fig. 2E and F) .
Discussion
This study demonstrated that secondary sarcomas developed at a younger age and significantly more frequently among retinoblastoma survivors, and the secondary sarcoma types correlated well with the primary cancer types. OS was a major sarcoma type in the retinoblastoma group, while nerve-related sarcomas (MPNST and PNET) developed only in the hematological cancer group. The CCSs with secondary sarcoma in the hematological cancer group tended to have worse prognoses than those in the other primary cancer groups. Table 4 summarizes the previous studies on secondary sarcoma in CCSs (5-9,11,14-24). The most prevalent secondary sarcoma was OS, followed by MPNST, ES and RMS. In the BCCSS study, the 94 cases of secondary bone sarcoma included 35 retinoblastomas and 21 bone/soft tissue sarcomas as the primary cancer, and the 54 cases of secondary soft tissue sarcomas included 16 retinoblastomas, eight brain tumors, six Wilms' tumors and 24 bone/soft tissue sarcomas as the primary cancer (5). Majority of CCSs with secondary sarcoma were males (male-to-female ratio, 1.5:1); this is consistent with the findings of our study. However, our study showed that there were no sex-related differences in the retinoblastoma group. Unfortunately, most previous studies did not include information on the sex ratio in the retinoblastoma group or the CCSS cohort did not include those with retinoblastoma as primary cancer.
The reported median latency period from primary cancer diagnosis to secondary sarcoma ranged from 8 to 19 years, which was consistent with our findings. The latency period varied only marginally according to the primary cancer group and the secondary sarcoma type, but the age at secondary sarcoma development was lower (less than 6 years) in the retinoblastoma group, and the age at diagnosis of the primary cancer was also lower among the CCSs with retinoblastoma ( Supplemental Fig). Among the treatment factors, exposure to radiotherapy is the most important risk factor of secondary sarcoma in CCSs in a dosedependent manner (7, 25, 26) . The percentage of secondary sarcomas that develop inside the radiation field vary widely from 56% (14) to 100% (26) . In this study, the prevalence of in-field secondary sarcomas was 76% (13 out of 17) among the CCSs who underwent irradiation. Tucker et al. reported that, in addition to radiation exposure, exposure to alkylating agents is also associated with risk of sarcoma after adjusting for radiation therapy (14) . Henderson et al. reported that anthracycline exposure is also associated with a risk of sarcoma after adjusting for the radiation dose (25) . Unfortunately, we were unable to detect any particular association Figure 1 . Cumulative incidence of secondary sarcoma in pediatric patients with any type of primary cancer. The cumulative incidence of secondary cancers as a function of time after the primary cancer diagnosis, over a maximum follow-up period of 30 years, analyzed using the Gray method: (A) sex, (B) primary cancer diagnostic groups, (C) radiotherapy, (D) surgery, (E) chemotherapy and (F) autologous stem cell transplantation (SCT). The cumulative incidence depended on the type of primary cancer (P < 0.001). The risk for secondary cancers was the highest in patients with retinoblastoma. Therapy-associated risk for secondary sarcoma was identified in patients receiving radiotherapy (C), surgery (D), or autologous SCT for primary cancers (F). between chemotherapeutic agents and the incidence of sarcoma due to the small number of secondary sarcoma cases in the current study.
The prognosis of CCSs with secondary sarcoma remains to be elucidated. Bisogno et al. reported that pediatric secondary soft tissue sarcomas can be cured using the same strategies as those used for de novo pediatric sarcomas, as 15 of 25 patients were alive with complete remission of their secondary sarcomas at the time of the last follow-up in their study (9) . Yonemoto et al. reported that the prognosis of OS as a secondary malignancy among CCSs may be more favorable than that of conventional OS (27) . We showed that cases of secondary sarcoma in the hematological cancer group had worse prognoses than those in the other primary cancer groups. The prognostic heterogeneity of secondary sarcoma may depend on the primary cancer group or a prior relapse of the primary cancer.
Our study has certain limitations as described in the previous article (11) . First, the study population was hospital based (not population based); therefore, external validation may be required to generalize our results to all Japanese CCSs. Second, the number of patients with secondary sarcomas may have been underestimated due to loss to follow-up. The follow-up duration was relatively short (median 8.4 years), and the number of patients with secondary sarcomas was relatively small in this study compared with those conducted in the United States and Europe.
Henderson et al. reported 108 cases of secondary sarcoma among CCSs in the CCSS study (6) ; however, that study did not include CCSs with retinoblastoma, which is a primary cancer associated with the highest rate of secondary OS. While the PanCareSurFup study included the largest number of CCSs with secondary bone/soft tissue sarcoma, detailed data on secondary sarcomas have not been reported to date (18, 19) . More detailed analyses on secondary sarcomas are warranted. Figure 2 . The overall survival curves for the patients with secondary sarcomas. Kaplan-Meier survival curves of the secondary sarcomas (A) according to the primary cancer type (P = 0.098, log-rank test), (B) the secondary sarcoma type (P = 0.425, log-rank test), (C) radiotherapy (P = 0.557, log-rank test), (D) the CDDP dose (P = 0.803, log-rank test), (E) the anthracycline dose (P = 0.026, log-rank test) and (F) prior relapse of primary cancer (P = 0.046, log-rank test). CDDP, cisplatin.
In conclusion, the significant risk factors for secondary sarcomas were a history of retinoblastoma as the primary cancer and prior Auto-SCT. The prognoses of CCSs with secondary sarcoma may depend on the primary cancer group or the prior relapse of the primary cancer.
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Supplementary data are available at Japanese Journal of Clinical Oncology online.
